The efficacy of the selective estrogen receptor modulator tamoxifen, the backbone of the treatment of estrogen receptor positive early breast cancer in postmenopausal women, is based on its bio-activation to 4-hydroxylated metabolites by hepatic cytochrome P450 (CYP) enzymes (Brauch et al. 2009). Here, ESR1 is linked to breast carcinoma.